Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT00928330
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT00927589
Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2019-04-16
- Target Recruit Count
- 33
- Registration Number
- NCT00923299
- Locations
- 🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 479
- Registration Number
- NCT00915018
- Locations
- 🇫🇷
Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, Perigueux, France
🇷🇴Institutul Oncologic Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Cluj, Romania
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 719
- Registration Number
- NCT00876395
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center Dept. of CBCC (2), Bakersfield, California, United States
🇺🇸New York Oncology Hematology NYOH Amsterdam, Albany, New York, United States
🇺🇸Texas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT00864175
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 10
- Registration Number
- NCT00847366
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 102
- Registration Number
- NCT00841828
- Locations
- 🇪🇸
Hospital General de Granollers, Granollers, Barcelona, Spain
🇪🇸Onkologikoa, Donostia-San Sebastián, Guipuzcoa, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00833963
- Locations
- 🇺🇸
Kendle International, Inc, Wilmington, North Carolina, United States
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT00826267
- Locations
- 🇺🇸
1200.44.01001 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇧🇷1200.44.12005 Boehringer Ingelheim Investigational Site, Ijui, Brazil
🇧🇷1200.44.12007 Boehringer Ingelheim Investigational Site, Natal, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.